Genetic modification of hematopoietic stem cells: Recent advances in the gene therapy of inherited diseases

Archives of Medical Research

Volumn 34, Issue 6, 2003, Pages 589-599

  Bueren, Juan A ^a,b   Guenechea, Guillermo ^a   Casado, José A ^a   Lamana, María Luisa ^a   Segovia, José C ^a  

^a Hematopoietic Gene Therapy Program   (Spain)

^b CIEMAT   (Spain)

Author keywords

Gene marking; Gene therapy; Immunodeficiencies; Inherited diseases; Retroviral vectors; Stem cells

Indexed keywords

ADENOSINE DEAMINASE; CD34 ANTIGEN; VIRUS VECTOR;

B LYMPHOCYTE; BLOOM SYNDROME; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CLONING; CELL NUCLEUS TRANSPLANTATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CYTOLOGY; DNA MODIFICATION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FANCONI ANEMIA; GENE MUTATION; GENE THERAPY; GENETIC CODE; HEMATOPOIESIS; HUMAN; IMMUNE DEFICIENCY; INHERITANCE; LEUKEMIA; MARKER GENE; METHODOLOGY; NONHUMAN; REVIEW; RISK; SIDE EFFECT; SOUTHERN BLOTTING; STEM CELL; T LYMPHOCYTE; UMBILICAL CORD BLOOD; VIRUS RECOMBINANT; XENOTRANSPLANTATION;

EID: 0346374761     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2003.09.004     Document Type: Review

References (99)

1. Parkman R. The application of bone marrow transplantation to the treatment of genetic diseases. Science. 232:1986;1373-1378.
2. Krivit W., Peters C., Shapiro E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 12:1999;167-176.
3. Chapel H., Geha R., Rosen F. Primary immunodeficiency diseases: an update. Clin Exp Immunol. 132:2003;9-15.
4. Guardiola P., Pasquini R., Dokal I., Ortega J.J., van Weel-Sipman M., Marsh J.C., Ball S.E., Locatelli F., Vermylen C., Skinner R., Ljungman P., Miniero R., Shaw P.J., Souillet G., Michallet M., Bekassy A.N., Krivan G., Di Bartolomeo P., Heilmann C., Zanesco L., Cahn J.Y., Arcese W., Bacigalupo A., Gluckman E. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 95:2000;422-429.
5. Gaipa G., Dassi M., Perseghin P., Venturi N., Corti P., Bonanomi S., Balduzzi A., Longoni D., Uderzo C., Biondi A., Masera G., Parini R., Bertagnolio B., Uziel G., Peters C., Rovelli A. Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplant. 31:2003;857-860.
6. Mollah Z.U., Aiba S., Manome H., Yoshino Y., Tagami H. Cord blood CD34+ cells differentiate into dermal dendritic cells in co-culture with cutaneous fibroblasts or stromal cells. J Invest Dermatol. 118:2002;450-460.
7. Krivit W., Sung J.H., Shapiro E.G., Lockman L.A. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 4:1995;385-392.
8. Matayoshi A., Brown C., DiPersio J.F., Haug J., Abu-Amer Y., Liapis H., Kuestner R., Pacifici R. Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells. Proc Natl Acad Sci USA. 93:1996;10785-10790.
9. Hildinger M., Abel K.L., Ostertag W., Baum C. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol. 73:1999;4083-4089.
10. Wahlers A., Kustikova O., Zipfel P.F., Itoh K., Koester M., Heberlein C., Li Z., Schiedlmeier B., Skerka C., Fehse B., Baum C. Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol Ther. 6:2002;313-320.
11. Porter C.D., Collins M.K., Tailor C.S., Parkar M.H., Cosset F.L., Weiss R.A., Takeuchi Y. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther. 7:1996;913-919.
12. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol. 72:1998;8463-8471.
13. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 72:1998;9873-9880.
14. Follenzi A., Ailles L.E., Bakovic S., Geuna M., Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 25:2000;217-222.
15. Guenechea G., Gan O.I., Inamitsu T., Dorrell C., Pereira D.S., Kelly M., Naldini L., Dick J.E. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther. 1:2000;566-573.
16. Dick J.E., Magli M.C., Huszar D., Phillips R.A., Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell. 42:1985;71-79.
17. Lemischka I.R., Raulet D.H., Mulligan R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell. 45:1986;917-927.
18. Jordan C.T., Lemischka I.R. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 4:1990;220-232.
19. Bernad A., Varas F., Gallego J.M., Almendral J.M., Bueren J.A. Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells. Br J Haematol. 87:1994;6-17.
20. Varas F., Bernad A., Almendral J.M., Bueren J.A. Relevance of myeloablative conditioning in the engraftment of limiting numbers of normal and genetically marked lympho-hematopoietic stem cells. Bone Marrow Transplant. 18:1996;981-989.
21. Varas F., Bernad A., Bueren J.A. Granulocyte colony-stimulating factor mobilizes into peripheral blood the complete clonal repertoire of hematopoietic precursors residing in the bone marrow of mice. Blood. 88:1996;2495-2501.
22. Brenner M.K., Rill D.R., Holladay M.S., Heslop H.E., Moen R.C., Buschle M., Krance R.A., Santana V.M., Anderson W.F., Ihle J.N. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 342:1993;1134-1137.
23. Brenner M.K., Rill D.R., Moen R.C., Krance R.A., Mirro J. Jr., Anderson W.F., Ihle J.N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85-86.
24. Deisseroth A.B., Zu Z., Claxton D., Hanania E.G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson W.F., Hester J., Korbling M., Durett A., Moen R., Berenson R., Heimfeld S., Hamer J., Calvert L., Tibbits P., Talpaz M., Kantarjian H., Champlin R., Reading C. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 83:1994;3068-3076.
25. Rill D.R., Santana V.M., Roberts W.M., Nilson T., Bowman L.C., Krance R.A., Heslop H.E., Moen R.C., Ihle J.N., Brenner M.K. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 84:1994;380-383.
26. Dunbar C.E., Cottler-Fox M., O'Shaughnessy J.A., Doren S., Carter C., Berenson R., Brown S., Moen R.C., Greenblatt J., Stewart F.M. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 85:1995;3048-3057.
27. Cornetta K., Srour E.F., Moore A., Davidson A., Broun E.R., Hromas R., Moen R.C., Morgan R.A., Rubin L., Anderson W.F., Hoffman R., Tricot G. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum Gene Ther. 7:1996;1323-1329.
28. Emmons R.V., Doren S., Zujewski J., Cottler-Fox M., Carter C.S., Hines K., O'Shaughnessy J.A., Leitman S.F., Greenblatt J.J., Cowan K., Dunbar C.E. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood. 89:1997;4040-4046.
29. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Birdsall-Maller I., Tennent B., McKenna S., Mobraaten L., Rajan T.V., Greiner D.L., Leitter E.H. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 154:1995;180-191.
30. Larochelle A., Vormoor J., Hanenberg H., Wang J.C., Bhatia M., Lapidot T., Moritz T., Murdoch B., Xiao X.L., Kato I., Williams D.A., Dick J.E. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 2:1996;1329-1337.
31. Dao M.A., Shah A.J., Crooks G.M., Nolta J.A. Engraftment and retroviral marking of CD34+ and CD34+CD38- human hematopoietic progenitors assessed in immune-deficient mice. Blood. 91:1998;1243-1255.
32. Nolta J.A., Hanley M.B., Kohn D.B. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood. 83:1994;3041-3051.
33. Zanjani E.D., Pallavicini M.G., Ascensao J.L., Flake A.W., Langlois R.G., Reitsma M., MacKintosh F.R., Stutes D., Harrison M.R., Tavassoli M. Engraftment and long-term expression of human fetal hemopoietic stem cells in sheep following transplantation in utero. J Clin Invest. 89:1992;1178-1188.
34. Nolta J.A., Dao M.A., Wells S., Smogorzewska E.M., Kohn D.B. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc Natl Acad Sci USA. 93:1996;2414-2419.
35. Kawashima I., Zanjani E.D., Almaida-Porada G., Flake A.W., Zeng H., Ogawa M. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood. 87:1996;4136-4142.
36. Almeida-Porada G., Porada C., Zanjani E.D. Adult stem cell plasticity and methods of detection. Rev Clin Exp Hematol. 5:2001;26-41.
37. Crooks G.M., Kohn D.B. Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells. Blood. 82:1993;3290-3297.
38. van Beusechem V.W., Bart-Baumeister J.A., Hoogerbrugge P.M., Valerio D. Influence of interleukin-3, interleukin-6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo. Gene Ther. 2:1995;245-255.
39. Guenechea G., Segovia J.C., Albella B., Lamana M., Ramírez M., Regidor C., Fernández M.N., Bueren J.A. Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood. 93:1999;1097-1105.
40. Barquinero J., Segovia J.C., Ramírez M., Limón A., Guenechea G., Puig T., Briones J., García J., Bueren J.A. Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. Blood. 95:2000;3085-3093.
41. Moritz T., Patel V.P., Williams D.A. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest. 93:1994;1451-1457.
42. Hanenberg H., Xiao X.L., Dilloo D., Hashino K., Kato I., Williams D.A. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 2:1996;876-882.
43. Guenechea G., Gan O.I., Dorrell C., Dick J.E. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2:2001;75-82.
44. Dick J.E., Guenechea G., Gan O.I., Dorrell C. In vivo dynamics of human stem cell repopulation in NOD/SCID mice. Ann N Y Acad Sci. 938:2001;184-190.
45. Horn P.A., Thomasson B.M., Wood B.L., Andrews R.G., Morris J.C., Kiem H.P. Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice versus nonhuman primates. Blood. 2003;. (Epub, ahead of print).
46. Kim H.J., Tisdale J.F., Wu T., Takatoku M., Sellers S.E., Zickler P., Metzger M.E., Agricola B.A., Malley J.D., Kato I., Donahue R.E., Brown K.E., Dunbar C.E. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood. 96:2000;1-8.
47. Schmidt M., Zickler P., Hoffmann G., Haas S., Wissler M., Muessig A., Tisdale J.F., Kuramoto K., Andrews R.G., Wu T., Kiem H.P., Dunbar C.E., Von Kalle C. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 100:2002;2737-2743.
48. Kelly P.F., Donahue R.E., Vandergriff J.A., Takatoku M., Bonifacino A.C., Agricola B.A., Metzger M.E., Dunbar C.E., Nienhuis A.W., Vanin E.F. Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34 positive cells marked with a RD114 pseudotyped oncoretroviral vector. Blood Cells Mol Dis. 30:2003;132-143.
49. Kohn D.B., Weinberg K.I., Nolta J.A., Heiss L.N., Lenarsky C., Crooks G.M., Hanley M.E., Annett G., Brooks J.S., el-Khoureiy A. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1:1995;1017-1023.
50. Kohn D.B., Hershfield M.S., Carbonaro D., Shigeoka A., Brooks J., Smogorzewska E.M., Barsky L.W., Chan R., Burotto F., Annett G., Nolta J.A., Crooks G., Kapoor N., Elder M., Wara D., Bowen T., Madsen E., Snyder F.F., Bastian J., Muul L., Blaese R.M., Weinberg K., Parkman R. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 4:1998;775-780.
51. Schmidt M., Carbonaro D.A., Speckmann C., Wissler M., Bohnsack J., Elder M., Aronow B.J., Nolta J.A., Kohn D.B., von Kalle C. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med. 9:2003;463-468.
52. Stephan V., Wahn V., Le Deist F., Dirksen U., Broker B., Muller-Fleckenstein I., Horneff G., Schroten H., Fischer A., de Saint Basile G. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 335:1996;1563-1567.
53. Arredondo-Vega F.X., Santisteban I., Richard E., Bali P., Koleilat M., Loubser M., Al-Ghonaium A., Al-Helali M., Hershfield M.S. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood. 99:2002;1005-1013.
54. Hirschhorn R., Yang D.R., Puck J.M., Huie M.L., Jiang C.K., Kurlandsky L.E. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 13:1996;290-295.
55. Ellis N.A., Ciocci S., German J. Back mutation can produce phenotype reversion in Bloom syndrome somatic cells. Hum Genet. 108:2001;167-173.
56. Wada T., Schurman S.H., Otsu M., Garabedian E.K., Ochs H.D., Nelson D.L., Candotti F. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci USA. 98:2001;8697-8702.
57. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., Oostra A.B., Veerman A.J., van Weel M., Pauli R.M., Shahidi N.T., Dokal I., Roberts I., Altay C., Gluckman E., Gibson R.A., Mathew C.G., Arwert F., Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 5:1997;137-148.
58. Gregory J.J. Jr., Wagner J.E., Verlander P.C., Levran O., Batish S.D., Eide C.R., Steffenhagen A., Hirsch B., Auerbach A.D. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci USA. 98:2001;2532-2537.
59. Gross M., Hanenberg H., Lobitz S., Friedl R., Herterich S., Dietrich R., Gruhn B., Schindler D., Hoehn H. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 98:2002;126-135.
60. Rio P., Segovia J.C., Hanenberg H., Casado J.A., Martínez J., Gottsche K., Cheng N.C., Van de Vrugt H.J., Arwert F., Joenje H., Bueren J.A. In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood. 100:2002;2032-2039.
61. Galimi F., Noll M., Kanazawa Y., Lax T., Chen C., Grompe M., Verma I.M. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood. 100:2002;2732-2736.
62. Bousso P., Wahn V., Douagi I., Horneff G., Pannetier C., Le Deist F., Zepp F., Niehues T., Kourilsky P., Fischer A., de Saint Basile G. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci USA. 97:2000;274-278.
63. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A., Anderson W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 270:1995;475-480.
64. Muul L.M., Tuschong L.M., Soenen S.L., Jagadeesh G.J., Ramsey W.J., Long Z., Carter C.S., Garabedian E.K., Alleyne M., Brown M., Bernstein W., Schurman S.H., Fleisher T.A., Leitman S.F., Dunbar C.E., Blaese R.M., Candotti F. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 101:2003;2563-2569.
65. Bordignon C., Notarangelo L.D., Nobili N., Ferrari G., Casorati G., Panina P., Mazzolari E., Maggioni D., Rossi C., Servida P., Ugazio A.G., Mavilio F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 270:1995;470-475.
66. Aiuti A., Vai S., Mortellaro A., Casorati G., Ficara F., Andolfi G., Ferrari G., Tabucchi A., Carlucci F., Ochs H.D., Notarangelo L.D., Roncarolo M.G., Bordignon C. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 8:2002;423-425.
67. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2002;2410-2413.
68. Noguchi M., Nakamura Y., Russell S.M., Ziegler S.F., Tsang M., Cao X., Leonard W.J. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 262:1993;1877-1880.
69. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:2000;669-672.
70. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.-P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346:2002;1185-1193.
71. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kuhlcke K., Eckert H.G., Fehse B., Baum C. Murine leukemia induced by retroviral gene marking. Science. 296:2002;497.
72. Bonini C., Grez M., Traversari C., Ciceri F., Marktel S., Ferrari G., Dinauer M., Sadat M., Aiuti A., Deola S., Radrizzani M., Hagenbeek A., Apperley J., Ebeling S., Martens A., Kolb H.J., Weber M., Lotti F., Grande A., Weissinger E., Bueren J.A., Lamana M., Falkenburg J.H.F., Heemskerk M.H.M., Austin T., Kornblau S., Marini F., Benati C., Magnani Z., Cazzaniga S., Toma S., Gallo-Stampino C., Introna M., Slavin S., Greenberg P.D., Bregni M., Mavilio F., Bordignon C. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 9:2003;367-369.
73. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M., Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 348:2003;255-256.
74. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science. 299:2003;320.
75. Marshall E. Gene therapy. What to do when clear success comes with an unclear risk? Science. 298:2002;510-511.
76. Larson R.C., Lavenir I., Larson T.A., Baer R., Warren A.J., Wadman I., Nottage K., Rabbitts T.H. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte. EMBO J. 15:1996;1021-1027.
77. Kaiser J. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk. Science. 299:2003;991.
78. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. HIV-1 integration in the human genome favors active genes and local. Cell. 110:2002;521-529.
79. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:2003;1749-1751.
80. Bordignon C., Bonini C., Verzeletti S., Nobili N., Maggioni D., Traversari C., Giavazzi R., Servida P., Zappone E., Benazzi E. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther. 6:1995;813-819.
81. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:1997;1719-1724.
82. Bibikova M., Beumer K., Trautman J.K., Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science. 300:2003;764.
83. Porteus M.H., Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science. 300:2003;763.
84. Yáñez R.J., Porter A.C. Differential effects of Rad52p overexpression on gene targeting and extrachromosomal homologous recombination in a human cell line. Nucleic Acids Res. 30:2002;740-748.
85. Ramezani A., Hawley T.S., Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-{beta} scaffold attachment region and the chicken {beta}-globin insulator. Blood. 101:2003;4717-4724.
86. Follenzi A., Sabatino G., Lombardo A., Boccaccio C., Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by. Hum Gene Ther. 13:2002;243-260.
87. Baum C., Dullmann J., Li Z., Fehse B., Meyer J., Williams D.A., von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101:2003;2099-2114.
88. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature. 410:2001;701-705.
89. Ferrari G., Cusella-De Angelis G., Coletta M., Paolucci E., Stornaiuolo A., Cossu G., Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 279:1998;1528-1530.
90. Mezey E., Chandross K.J., Harta G., Maki R.A., McKercher S.R. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science. 290:2000;1779-1782.
91. Lagasse E., Connors H., Al-Dhalimy M., Reitsma M., Dohse M., Osborne L., Wang X., Finegold M., Weissman I.L., Grompe M. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 6:2000;1229-1234.
92. Krause D.S., Theise N.D., Collector M.I., Henegariu O., Hwang S., Gardner R., Neutzel S., Sharkis S.J. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 105:2001;369-377.
93. Bjornson C.R., Rietze R.L., Reynolds B.A., Magli M.C., Vescovi A.L. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science. 283:1999;534-537.
94. Terada N., Hamazaki T., Oka M., Hoki M., Mastalerz D.M., Nakano Y., Meyer E.M., Morel L., Petersen B.E., Scott E.W. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 416:2002;542-545.
95. Wang X., Willenbring H., Akkari Y., Torimaru Y., Foster M., Al-Dhalimy M., Lagasse E., Finegold M., Olson S., Grompe M. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 422:2003;897-901.
96. LaBarge M.A., Blau H.M. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell. 111:2002;589-601.
97. Grove J.E., Lutzko C., Priller J., Henegariu O., Theise N.D., Kohn D.B., Krause D.S. Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol. 27:2002;645-651.
98. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-González X.R., Reyes M., Lenvik T., Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., Low W.C., Largaespada D.A., Verfaillie C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:2002;41-49.
99. Rideout W.M. 3rd, Hochedlinger K., Kyba M., Daley G.Q., Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 109:2002;17-27.